Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Atricure Inc (ATRC)

Atricure Inc (ATRC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference Business Wire - Wed May 27, 7:00AM CDT

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative...

ATRC : 27.67 (-1.50%)
MarketBeat.com
AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook MarketBeat - Tue May 12, 2:10PM CDT

AtriCure (NASDAQ:ATRC) executives said the company’s 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and expanding...

ATRC : 27.67 (-1.50%)
AtriCure Reports First Quarter 2026 Financial Results Business Wire - Tue May 5, 3:01PM CDT

First Quarter 2026 worldwide revenue of $141.2 million, an increase of 14.3% year over year First Quarter 2026 profitability improved, with net income of $0.1 million and adjusted EBITDA...

ATRC : 27.67 (-1.50%)
AtriCure to Participate in the 2026 Bank of America Securities Health Care Conference Business Wire - Tue Apr 28, 7:00AM CDT

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative...

ATRC : 27.67 (-1.50%)
AtriCure to Announce First Quarter 2026 Financial Results Business Wire - Tue Apr 14, 7:00AM CDT

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative...

ATRC : 27.67 (-1.50%)
AtriCure to Participate in the Citizens Life Sciences Conference Business Wire - Tue Feb 24, 7:00AM CST

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative...

ATRC : 27.67 (-1.50%)
AtriCure: Q4 Earnings Snapshot AP - Tue Feb 17, 3:34PM CST

AtriCure: Q4 Earnings Snapshot

ATRC : 27.67 (-1.50%)
AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results Business Wire - Tue Feb 17, 3:01PM CST

Fourth Quarter 2025 worldwide revenue of $140.5 million – an increase of 13.1% year over year Fourth Quarter 2025 net income of $1.8 million and positive adjusted EBITDA of $19.9 million...

ATRC : 27.67 (-1.50%)
AtriCure to Announce Fourth Quarter and Full Year 2025 Financial Results Business Wire - Tue Jan 27, 7:00AM CST

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative...

ATRC : 27.67 (-1.50%)
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026 Business Wire - Mon Jan 12, 9:21AM CST

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative...

ATRC : 27.67 (-1.50%)

Barchart Exclusives

The DRAM Shortage to Extend Into 2028. This Means Micron Stock Could Easily Double From Here. Barchart - 42 minutes ago
Memory supply shortage may not be resolved anytime soon, as analysts revise their MU price target upward. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.